A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and feasible for multiple myeloma patients when given around the time of an autologous stem cell transplant (ASCT). These are the findings of a…
Read more
The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton Therapeutics’ investigational continuous delivery of low-dose lenalidomide, in people with multiple myeloma. “I’m thrilled to be the study’s lead investigator and excited about the…
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT) for people with multiple myeloma. AHSCT’s success depends on efficacious mobilization of healthy blood stem cells into the bloodstream for collection and subsequent transplant.
While myeloma doesn’t have a cure yet, its prognosis has greatly improved due to an increase in available treatments.
Myeloma is a cancer that forms from a type of white blood cell called B-cells. Learn more about the disease here.
Mutations in critical oncogenes or tumor suppressor genes in B-cells can cause myeloma. Learn more about the causes here.
Symptoms vary from patient to patient and may be mild in the early stages. Learn more about the symptoms here.
Get regular updates to your inbox.
